To the Editor: Weight gain and elevations of total cholesterol or triglyceride levels are frequent metabolic side effects of second-generation antipsychotics (SGAs). Clozapine, olanzapine, and quetiapine have been associated with moderate increases in serum triglyceride levels, an early sign of impending metabolic syndrome. 1,2 We report on an excessive quetiapine-induced hypertriglyceridemia, validated by reexposure to the medication. Letters to the editor Case report. Mr A, a 54-year-old male patient suffering from delusions of persecution, formal thought disorder, and marked cognitive and psychomotor impairment, fulfilled the DSM-IV criteria of paranoid schizophrenia. Before antipsychotic treatment was initiated, his triglyceride (165 mg/dL) and total cholesterol (207 mg/dL) levels were within normal ranges (body weight = 72.5 kg, body mass index [BMI] = 23.2 kg/m 2 ). Mr A's symptoms did not respond to olanzapine, zuclopenthixol, or risperidone, but improved with quetiapine (800 mg/d, serum level = 986 µg/L).
In contrast to reports of moderately increased triglyceride levels with quetiapine, 1,2 we observed an excessive elevation of +512%, quite similar to a recent observation with risperidone. 3 We were able to exclude abnormal nutrition, pathologic leptin levels, or glucose metabolism. SGAs are thought to disturb lipid metabolism via antiserotonergic and antihistaminergic effects, but genetic liability might also be important. Until a more precise understanding might allow individual predictions of drug tolerability, general metabolic monitoring and dietary consultation for patients with psychotic disorders appear indispensable.
